Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 242Neoplasms, Plasma Cell 50Lymphoma 45Lymphoma, Mantle-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Lymphoma, Non-Hodgkin 30Recurrence 29Lymphoma, Follicular 24Leukemia, Myeloid, Acute 24Lymphoma, Large B-Cell, Diffuse 23Waldenstrom Macroglobulinemia 22Lymphoma, B-Cell, Marginal Zone 20Leukemia 20Immunoglobulin Light-chain Amyloidosis 18Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 12Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Hodgkin Disease 11Burkitt Lymphoma 10Breast Neoplasms 10Lymphoma, T-Cell, Peripheral 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Lung Neoplasms 9Immunoblastic Lymphadenopathy 9Hematologic Neoplasms 9Prostatic Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell 8

Interventions

olaparib 1liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasm Epithelial × Bortezomib × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡